The Senate Judiciary Committee recently made significant progress by moving forward with six bills aimed at addressing prescription drug pricing, particularly focusing on overhauling the patent system. This marks a milestone in a long-standing issue that has bipartisan support but has struggled to make any real changes in the past. The urgency surrounding this issue is palpable, with both constituents and policymakers pushing for action. However, given the history of failed attempts to pass reform, there is still uncertainty about whether the 119th Congress is truly prepared to take action.
Congress’s approval rating of 29% reflects a lack of effectiveness in getting things done, especially in healthcare policy. Reforms related to Pharmacy Benefit Managers and drug patents have often been delayed or ignored, leaving many stakeholders frustrated. The influence of lobbyists and general inertia within Congress have contributed to the stagnation of these critical issues.
Despite the challenges of finding bipartisan consensus in today’s political landscape, there is a widespread agreement on the need for pharmaceutical patent reform. The high prices of brand-name drugs in the U.S. are partly attributed to tactics used by drug manufacturers to prolong their monopoly pricing and block competition from generic alternatives. Former FDA Commissioner Scott Gottlieb and former Federal Trade Commissioner Lina Khan have both highlighted the need to address these anticompetitive practices.
Patients For Affordable Drugs NOW founder, David Mitchell, a cancer patient himself, has been vocal about the anticompetitive tactics employed by drug companies to maintain monopolies. Additionally, the Initiative for Medicines, Access & Knowledge advocates for drug patent reform, citing the detrimental impact of excessive patent use on medication prices for American patients.
Studies have shown that a significant number of new drug patents are for existing medications, and many best-selling drugs receive additional patents to extend their market exclusivity. This practice, known as “evergreening,” contributes to high drug costs and limits access to more affordable generic alternatives.
While the pharmaceutical industry argues that patent reform is unnecessary due to the prevalence of generics in the market, lawmakers are keen on curbing abuses of the system. Recent legislative efforts have focused on addressing anti-competitive practices and promoting a more competitive market for generics and biosimilars.
The Senate Judiciary Committee’s advancement of six bills targeting drug pricing and patent reform is a positive step forward. These bills aim to tackle issues such as “patent thickets” and “product hopping,” as well as limiting pay-for-delay deals and sham citizen petitions that hinder generic drug approvals. Despite past setbacks, there is hope that meaningful changes may finally be on the horizon in this Congress. Only time will tell if these efforts will lead to tangible reform in the prescription drug pricing landscape.
